Boothbay Fund Management LLC bought a new stake in shares of ABIVAX Société Anonyme (NASDAQ:ABVX - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 406,903 shares of the company's stock, valued at approximately $2,979,000. Boothbay Fund Management LLC owned 0.64% of ABIVAX Société Anonyme at the end of the most recent reporting period.
A number of other large investors have also recently made changes to their positions in ABVX. GAMMA Investing LLC purchased a new stake in ABIVAX Société Anonyme during the 4th quarter worth about $29,000. R Squared Ltd purchased a new stake in shares of ABIVAX Société Anonyme in the fourth quarter worth about $36,000. Guggenheim Capital LLC bought a new position in shares of ABIVAX Société Anonyme in the fourth quarter valued at approximately $92,000. Springhill Fund Asset Management HK Co Ltd purchased a new position in ABIVAX Société Anonyme during the fourth quarter valued at approximately $1,520,000. Finally, Kennedy Capital Management LLC increased its holdings in ABIVAX Société Anonyme by 0.7% during the 4th quarter. Kennedy Capital Management LLC now owns 225,470 shares of the company's stock worth $1,650,000 after acquiring an additional 1,656 shares during the period. 47.91% of the stock is owned by institutional investors.
ABIVAX Société Anonyme Price Performance
Shares of NASDAQ:ABVX traded up $0.28 during trading on Friday, reaching $7.19. The company had a trading volume of 138,291 shares, compared to its average volume of 132,596. The company has a fifty day moving average of $6.60 and a two-hundred day moving average of $7.53. ABIVAX Société Anonyme has a 12 month low of $4.77 and a 12 month high of $15.06.
Analysts Set New Price Targets
Several research analysts have commented on the stock. Morgan Stanley reissued an "equal weight" rating and issued a $12.00 price target on shares of ABIVAX Société Anonyme in a report on Thursday, March 20th. JMP Securities reissued a "market outperform" rating and set a $33.00 price objective on shares of ABIVAX Société Anonyme in a research note on Wednesday. One analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, ABIVAX Société Anonyme currently has a consensus rating of "Buy" and a consensus price target of $34.00.
Check Out Our Latest Stock Report on ABVX
ABIVAX Société Anonyme Profile
(
Free Report)
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.
Further Reading
Before you consider ABIVAX Société Anonyme, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ABIVAX Société Anonyme wasn't on the list.
While ABIVAX Société Anonyme currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
